Why do Ozempic and Wegovy seem to treat everything?
Here’s a summary of this article I contributed to. Read the full article on NewScientist.
Origins and Development:
Ozempic is based on the hormone GLP-1, discovered in the 1980s.
Initially developed for diabetes treatment, Novo Nordisk launched semaglutide (Ozempic) in 2017 as a weekly injection, followed by Wegovy in 2021 for obesity.
Wegovy helps users lose 15% of body weight in one year despite its high cost ($1,300/month).
Mechanisms of Action:
GLP-1 agonists:
Signal the pancreas to release insulin, lowering blood sugar.
Slow digestion, keeping users fuller longer.
Impact brain areas related to motivation, reward, and appetite.
Potentially improve gut flora and metabolism.
Health Benefits:
Proven to improve heart health, reduce cholesterol, and lower the risk of stroke or heart attack.
Anti-inflammatory properties benefit conditions like asthma, arthritis, psoriasis, and sepsis.
Promising results for Alzheimer's: reduced brain shrinkage and slower cognitive decline.
May aid in addiction treatment by reducing reward-driven behaviors for food, alcohol, and drugs.
Mental Health Impact:
Users report reduced "food noise," better emotional balance, and improved mood.
Research suggests it enhances brain function and mood-regulating neurotransmitters like dopamine and serotonin.
Side Effects and Concerns:
Common issues include constipation and muscle wasting.
"Ozempic face": accelerated facial aging due to fat tissue loss.
Questions remain about long-term effects, including potential unintended consequences.
Future Potential:
Researchers are exploring its applications for cancer, arthritis, and more.
While some benefits will hold up under rigorous trials, others may not.
Key Takeaway:
Ozempic and similar drugs are groundbreaking but require further study to fully understand their mechanisms and broader implications.
